Prescription medication · Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)

levomilnacipran

Also sold as Fetzima. Fetzima is used to treat major depressive disorder (MDD) in adults.

Data updated 2026-05-15

1,858
FDA reportsRarely reported
11
InteractionsSeveral interactions
$16.13
Brand price (NADAC)

What the data shows

levomilnacipran (Fetzima) is a prescription Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), among the least-reported drugs the FDA tracks (1,858 FDA reports), with 11 documented drug interactions.

Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.

levomilnacipran (Fetzima) is a prescription Serotonin-Norepinephrine Reuptake Inhibitor (SNRI). Fetzima is used to treat major depressive disorder (MDD) in adults.

Fetzima is a medicine used to treat major depressive disorder (MDD) in adults. It helps to improve your mood by affecting certain chemicals in the brain.

Drug Pricing (NADAC)

Brand Price

$16.13/unit

Generic Available

No

ABBVIE

Pricing data from NADAC (CMS), effective January 2, 2024. Compare all drug costs →

View Alternatives → Compare with Another Drug → Full Side Effects Report →

What it does

Fetzima is used to treat major depressive disorder (MDD) in adults.

Common side effects

Nausea, Constipation, Increased sweating

Key warnings

Antidepressants may increase the risk of suicidal thoughts and behaviors in young adults.

The sections below are summarized in plain English from levomilnacipran's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.

How It Works

Fetzima is a type of drug called a serotonin-norepinephrine reuptake inhibitor (SNRI). It works by increasing the levels of serotonin and norepinephrine in your brain. These chemicals can help improve your mood and reduce symptoms of depression.

Side Effects (from patient reports)

Based on 1,858 FDA adverse event reports.

Most-reported reactions

Adverse reactions in FAERS for levomilnacipran, by number of reports

reports

What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.

Source FDA Adverse Event Reporting System (FAERS) As of 2025

Reports over time

Adverse-event reports filed for levomilnacipran each year to the FDA Adverse Event Reporting System (FAERS).

0100200300400 2013201520172019202120232025 157

Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.

Where levomilnacipran sits

levomilnacipran has more FDA adverse-event reports than 12% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.

fewest reports most reports

Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is levomilnacipran; the line is the median (50th percentile).

FDA Adverse Event Report Analysis

Detailed analysis of 1,858 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2013–2025.

Total Reports

1,858

Reports Mentioning Death

154

8.3% of reports — not proof of cause

Hospitalization Reports

283

Top Indication

Product Used For Unknown Indication

Gender Distribution

Female 1,310 (76%)
Male 407 (24%)

Age Distribution

0–17 31
18–44 469
45–64 396
65–74 110
75+ 36

Most Reported Adverse Reactions (FAERS)

# Reaction Reports
3 PAIN 210
4 VOMITING 208
5 MEMORY IMPAIRMENT 189
6 PARAESTHESIA 179
7 HYPOAESTHESIA 178
8 ABDOMINAL PAIN UPPER 175
9 MIGRAINE 170
10 GASTROOESOPHAGEAL REFLUX DISEASE 168
12 TASTE DISORDER 157
13 EPILEPSY 155
14 BLEPHAROSPASM 152
15 NAUSEA 143
16 CONDITION AGGRAVATED 135
17 DEPRESSION 114
18 HEADACHE 112

Reactions in Death Reports

MATERNAL EXPOSURE DURING PREGNANCY 91
CONDITION AGGRAVATED 89
OVERLAP SYNDROME 73
HYPOAESTHESIA 29
VOMITING 29
ABDOMINAL PAIN UPPER 27
DEATH 26
MEMORY IMPAIRMENT 26
PARAESTHESIA 26
RHEUMATOID ARTHRITIS 26

Reactions in Hospitalization Reports

VOMITING 43
PAIN 39
HYPOAESTHESIA 38
MEMORY IMPAIRMENT 35
CONDITION AGGRAVATED 34
HYPERTENSION 33
PARAESTHESIA 33
ABDOMINAL PAIN UPPER 32
CHEST PAIN 32
GASTROOESOPHAGEAL REFLUX DISEASE 32

Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation

Serious Warnings

Antidepressants may increase the risk of suicidal thoughts and behaviors in young adults. Your doctor should closely watch you for worsening depression or suicidal thoughts. Fetzima is not approved for use in children.

Known Drug Interactions

moderate linezolid

Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue [see Dosage and Administration ( 2.5 , 2.6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5.2 )] . Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drugs Clinical Impact: Concomitant use of FETZIMA with other serotonergic drugs increases the risk of serotonin syndrome.

Mechanism: Both of these medications increase the levels of a brain chemical called serotonin. If levels get too high, it can lead to a serious and potentially life-threatening reaction.

moderate phenelzine

Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drugs Clinical Impact: Concomitant use of FETZIMA with other serotonergic drugs increases the risk of serotonin syndrome.

Mechanism: Both drugs increase serotonin levels in the brain, which can lead to a dangerous buildup called serotonin syndrome.

Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drugs Clinical Impact: Concomitant use of FETZIMA with other serotonergic drugs increases the risk of serotonin syndrome.

Mechanism: These drugs both raise serotonin levels, and using them at the same time can cause too much serotonin to build up in your body.

moderate selegiline

Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drugs Clinical Impact: Concomitant use of FETZIMA with other serotonergic drugs increases the risk of serotonin syndrome.

Mechanism: Taking these medications together can cause serotonin levels to become dangerously high, leading to a condition called serotonin syndrome.

Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.

Mechanism: Both of these medicines increase the levels of a brain chemical called serotonin. Taking them together can cause serotonin levels to become dangerously high.

Check all your medications →

This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.

Common Questions

What should I do if I feel worse after starting Fetzima?
Tell your doctor right away if you feel your depression is getting worse or if you have suicidal thoughts.
Can I drink alcohol while taking Fetzima?
No, you should avoid drinking alcohol while taking Fetzima.
What if I have kidney problems?
Tell your doctor if you have kidney problems, as your dose may need to be adjusted.
Can I stop taking Fetzima suddenly?
No, you should not stop taking Fetzima suddenly. Talk to your doctor about slowly reducing the dose to avoid withdrawal symptoms.
Will Fetzima affect my other medications?
Fetzima can interact with other medications. Tell your doctor about all the medicines you take, including over-the-counter drugs and supplements.
How long does it take for Fetzima to start working?
It may take several weeks for Fetzima to start working. Be patient and continue taking the medicine as prescribed.
What if I have bipolar disorder?
Tell your doctor if you have bipolar disorder, as Fetzima may trigger mania or hypomania.
Can Fetzima cause sexual side effects?
Yes, Fetzima can cause sexual side effects. Talk to your doctor if you experience any sexual problems.
What if I need surgery?
Tell your doctor if you are taking Fetzima before any surgery or dental procedure.
Is there a generic version of Fetzima?
No, there is currently no generic version of Fetzima available.
What are the common side effects of levomilnacipran?
The registry lists Nausea, Constipation, Increased sweating, Increased heart rate, Erectile dysfunction among the most-reported FAERS reaction terms for levomilnacipran. The compiled record contains 1,858 FDA adverse-event reports. These counts are not an individual symptom assessment.
Does levomilnacipran interact with other medications?
The registry has 11 documented interaction rows for levomilnacipran. Notable source-record pairings include linezolid, phenelzine, tranylcypromine. These rows are not a complete medication review.
What drug class is levomilnacipran?
levomilnacipran belongs to the Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) drug class. It requires a prescription (Rx). Fetzima is used to treat major depressive disorder (MDD) in adults.
What pregnancy or breastfeeding source fields are listed for levomilnacipran?
The FDA label for levomilnacipran contains product-specific pregnancy or breastfeeding language. PlainMeds does not apply that source text to an individual.

Other drugs grouped near levomilnacipran - same-class peers and common alternatives.

Compare levomilnacipran vs acamprosate side-by-side →

Compare beyond drug class

Nationwide peers by FAERS volume & death-report share

Two PlainMeds-derived comparison paths for levomilnacipran: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.

Medication Guides

Save on levomilnacipran

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for levomilnacipran

The FDA label for levomilnacipran (sold under brand names such as Fetzima) classifies it as a prescription-only medication in the Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) class. Fetzima is used to treat major depressive disorder (MDD) in adults. Official labeling lists 9 commonly reported side effects, including Nausea, Constipation, Increased sweating.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 1,858 voluntary reports. The database also lists 11 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS.

Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.

Last updated: April 30, 2024

PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.

Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.

All federal data sources used on this page